Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction
by Zacks Equity Research
Novo Nordisk's (NVO) Ozempic gets FDA approval for reducing the risk of major adverse cardiovascular events in people with type II diabetes and established CVD.
Nektar's Pain Drug Gets Adverse Advisory Committee Decision
by Zacks Equity Research
Nektar (NKTR) to stop development of chronic pain candidate, NKTR-181, following two FDA advisory committees' decision to not recommend its approval.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $64.31, moving -1.11% from the previous trading session.
The Zacks Analyst Blog Highlights: Chevron, Accenture, Adobe Systems, Gilead Sciences and Honda Motor
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chevron, Accenture, Adobe Systems, Gilead Sciences and Honda Motor
Stock Research Reports for Chevron, Accenture, Adobe & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), Accenture (ACN) and Adobe Systems (ADBE).
Gilead (GILD) Inks License Deal with Xencor for HIV Candidate
by Zacks Equity Research
Gilead Sciences (GILD) entered into a technology license agreement with Xencor for use of XmAb antibody technologies in investigational agents for HIV.
Agenus Initiates Phase I Study on Oncology Candidate AGEN1223
by Zacks Equity Research
Agenus (AGEN) initiates phase I study on AGEN1223, a novel bi-specific antibody designed to deplete regulatory T cells in the tumor micro environment.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $65.12, marking a -0.81% move from the previous day.
Novo Nordisk's Shares Up in a Year on Pipeline Progress
by Zacks Equity Research
Novo Nordisk's (NVO) shares have gained in the past year as it makes significant progress in pipeline development.
GILD vs. TECH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GILD vs. TECH: Which Stock Is the Better Value Option?
Spring Bank (SBPH) Stops Dosing in HBV Studies, Stock Down
by Zacks Equity Research
Spring Bank (SBPH) declines as it stops dosing and enrolling patients in phase IIb studies on inarigivir.
Gilead (GILD) Partners With Eisai for RA Candidate in Japan
by Zacks Equity Research
Gilead Sciences (GILD) collaborates with Eisai for the distribution and co-promotion of its rheumatoid arthritis candidate, filgotinib. The companies will jointly commercialize the drug, if approved.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $66.72, moving -0.04% from the previous trading session.
GlaxoSmithKline's Long-Acting HIV Regimen Gets CRL From FDA
by Zacks Equity Research
GlaxoSmithKline's (GSK) ViiV Healthcare receives a CRL from the FDA for its application seeking approval of its investigational long-acting injectable therapy, which is a combination of cabotegravir and J&J's Edurant.
Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib
by Zacks Equity Research
Gilead (GILD) files an NDA for filgotinib with the FDA for the treatment of adults with moderate-to-severe rheumatoid arthritis.
The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals
Biotech Stock Outlook: M&A Activity Retains Growth Streak
by Ekta Bagri
The biotech sector enjoys a good run in 2019 on the back of the M&A activities and positive pipeline updates underway. We expect this momentum to stay in 2020 as well.
Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More
by Zacks Equity Research
The biotech sector was in focus this week with pipeline and regulatory updates from quite a few players.
Gilead (GILD) Announces Top-Line Results From NASH Study
by Zacks Equity Research
Gilead's (GILD) mid-stage study on combination and monotherapy investigational treatments for advanced fibrosis due to NASH fails to meet the primary endpoint.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $66.12 in the latest trading session, marking a +0.53% move from the prior day.
Gilead Teams Up With Kiniksa, Submits BLA for CAR T Therapy
by Zacks Equity Research
Gilead (GILD) collaborates with Kiniksa for a combination study and submits BLA for CAR T therapy candidate.
Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar
by Zacks Equity Research
The biotech sector witnesses pipeline updates from the annual ASH meet.
The Zacks Analyst Blog Highlights: Toyota, CVS, 3M, Gilead and Goldman
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Toyota, CVS, 3M, Gilead and Goldman
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $67.08, moving +0.22% from the previous trading session.
Fate (FATE) Announces Encouraging Data on Immunotherapies
by Zacks Equity Research
Fate (FATE) gains on positive data from cellular immunotherapies and preclinical study data.